Skip to content

Clinical trials

Fatty Liver trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Fatty Liver Phase: Not applicable Clear all

221 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20053
20066
20075
20084
20096
20104
201110
20126
20136
20147
201512
20167
20176
201811
201916
202010
202118
202214
202322
202419
202514
202613

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed133
Unknown status30
Recruiting23
Not yet recruiting10
Withdrawn9
Terminated7
Enrolling by invitation5
Active, not recruiting4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Cairo University4
Seoul National University Hospital4
University of Aarhus4
Massachusetts General Hospital3
University of Lausanne3
University of Palermo3
University of Texas Southwestern Medical Center3
Uppsala University3
AdventHealth Translational Research Institute2
Arkansas Children's Hospital Research Institute2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Fatty Liver221
Non-alcoholic Fatty Liver Disease89
Obesity40
Insulin Resistance28
Metabolic Syndrome22
Liver Cirrhosis19
Diabetes Mellitus, Type 214
Diabetes Mellitus12
Liver Diseases12
Inflammation8

Trials

Showing 76 to 100 of 221. Each trial links to its page on Pharma Observatory.

121 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.